S&P Futures
4,159.00 +12.25 (+0.30%) Dow Futures
32,855.00 +98.00 (+0.30%) Nasdaq Futures
13,284.25 +55.50 (+0.42%) Russell 2000 Futures
1,927.30 +5.50 (+0.29%) Crude Oil
89.89 +0.88 (+0.99%) Gold
1,793.60 +2.40 (+0.13%)
Anixa Biosciences, Inc. (ANIX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.8000 |
| Open | 3.7900 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 3200 |
| Day's Range | 3.7280 - 4.0856 |
| 52 Week Range | 2.3000 - 5.8700 |
| Volume | |
| Avg. Volume | 86,472 |
| Market Cap | 121.275M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5200 |
| Earnings Date | Jun 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ANIX
Related Research
- Anixa Biosciences, Inc.Technical Assessment: Neutral in the Intermediate-TermAfter hitting extreme levels early in the summer, sentiment has become more positive -- which is understandable considering the stock-price rally off mid-June lows. This is bullish in the short-term, as some of the sideline money comes back into the stock market. Speaking anecdotally, many professional market participants (at least the talking heads on the business channels) are still calling this a bear-market rally. These experts always have an opinion and love the shining lights. But we will wait until the weight of actual evidence points to a bear-market rally or a new bull market.RatingFair ValueEconomic Moat3 days agoArgus Research
- PR Newswire
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
- PR Newswire
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research. The article is titled, "Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas." This paper authored by Suparna Mazumder, Ph.D., Valerie Swank, MS, Nina Dvorina
- Simply Wall St.
Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
